Danny McClure, DO
Psychiatry · Tamuning, GUNPI 1073855409
Payments from drug & device makers
Across 866 payments — averaging $294.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$84K
- Axsome Therapeutics, Inc.$71K
- Alkermes, Inc.$57K
- Otsuka America Pharmaceutical, Inc.$33K
- Biogen$2K
- AbbVie$2K
- plus $6K from 23 others
What the payments were for
- Consulting fees$52,40221%
- Speaking & faculty fees$166,86265%
- Travel & lodging$18,8307%
- Food & beverage$16,8507%
- Education$1220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 112 | $84,247 |
| Axsome Therapeutics, Inc. | 124 | $71,229 |
| Alkermes, Inc. | 98 | $56,992 |
| Otsuka America Pharmaceutical, Inc. | 96 | $33,065 |
| Biogen | 4 | $2,018 |
| AbbVie(2 entities) | 93 | $1,620 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 47 | $906 |
| Takeda Pharmaceuticals U.S.A., Inc. | 52 | $796 |
| Sunovion Pharmaceuticals Inc. | 35 | $520 |
| Almatica Pharma LLC | 23 | $511 |
| Supernus Pharmaceuticals, Inc. | 38 | $505 |
| Lundbeck LLC | 31 | $499 |
| Johnson & Johnson | 16 | $401 |
| Bausch Health US, LLC | 20 | $374 |
| Vanda Pharmaceuticals Inc. | 17 | $350 |
| Corium, LLC | 17 | $233 |
| Eisai Inc. | 10 | $156 |
| Teva Pharmaceuticals USA, Inc. | 6 | $117 |
| Ironshore Pharmaceuticals Inc. | 6 | $113 |
| Idorsia Pharmaceuticals US Inc | 5 | $83 |
| Tris Pharma Inc | 4 | $72 |
| Harmony Biosciences LLC | 2 | $55 |
| Noven Therapeutics, LLC | 3 | $50 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $41 |
| Adlon Therapeutics L.p. | 2 | $41 |
| Tempus AI, Inc | 1 | $19 |
| Amgen | 1 | $19 |
| Gilead | 1 | $19 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few psychiatry providers in Guamto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 19 | $160,919 |
| RexultiBrexpiprazole | 12 | $25,376 |
| AuvelityDextromethorphan Hbr/Bupropion | 14 | $23,065 |
| TrintellixVortioxetine Hydrobromide | 18 | $13,303 |
| Methylphenidate ErMethylphenidate Hcl | 19 | $2,957 |
| Quetiapine Fumarate | 56 | $2,947 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 17 | $2,485 |
| Bupropion XlBupropion Hcl | 59 | $1,724 |
| Clonazepam | 55 | $1,123 |
| Trazodone Hcl | 43 | $1,048 |
| Hydroxyzine Hcl | 11 | $975 |
| Duloxetine Hcl | 38 | $967 |
| Lamotrigine | 53 | $839 |
| Gabapentin | 16 | $787 |
| Oxcarbazepine | 12 | $743 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $84,247 | $160,91919 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $33,065 | $25,37612 claims |
| Axsome Therapeutics, Inc.Auvelity | $71,229 | $23,06514 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $796 | $13,30318 claims |
| Almatica Pharma LLCSertraline Hcl | $511 | $10916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychiatry providers in Guamon file to place this against a meaningful peer group, so we don't.
Other psychiatry in Tamuning
- Adrian CuellarAgana Heights$125
- Laura PostTumon$63
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.